Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Operating Leases of $7.0 million for Q1 2026, up 84.94% year-over-year from $3.8 million in Q1 2025, and up 1.6% quarter-over-quarter from $6.9 million in Q4 2025.
Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2026) Analysis & Trends
Protalix BioTherapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- In Q1 2026, Operating Leases rose 84.94% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $7.0 million (up 84.94% YoY), while the FY2025 annual figure was $6.9 million, up 72.31% from the prior year.
- Operating Leases for Q1 2026 stood at $7.0 million, up from $6.9 million in the prior quarter.
- The five-year high for Operating Leases was $7.0 million in Q1 2026, with the low at $3.8 million in Q1 2025.
- The 5-year median for Operating Leases is $4.2 million (2022), against an average of $4.7 million.
- The sharpest annual moves came in 2025 and 2026: Operating Leases declined 15.29% in 2025, then jumped 84.94% in 2026.
- Protalix BioTherapeutics' Operating Leases stood at $4.2 million in 2022, then increased by 10.84% to $4.6 million in 2023, then slipped by 12.88% to $4.0 million in 2024, then jumped by 72.31% to $6.9 million in 2025, then climbed by 1.6% to $7.0 million in 2026.
- Business Quant data shows PLX's Operating Leases at $7.0 million in Q1 2026, $6.9 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - |
| 10 | Protalix BioTherapeutics | 194.77 Mn | 154.11 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.54 Mn |
| Mar 31, 2026 | 7.05 Mn |
| Dec 31, 2025 | 6.94 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Mar 31, 2025 | 3.81 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Mar 31, 2024 | 4.50 Mn |
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 4.50 Mn |
| Jun 30, 2023 | 4.58 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 4.03 Mn |
| Jun 30, 2022 | 3.89 Mn |
| Mar 31, 2022 | 4.19 Mn |
| Dec 31, 2021 | 4.38 Mn |
| Sep 30, 2021 | 4.44 Mn |